Brief: An2 Therapeutics To Initiate Phase 2 Trial Later This Year
30/06/2025 12:21
June 30 (Reuters) - AN2 Therapeutics Inc ANTX.O: AN2 THERAPEUTICS REPORTS KEY INSIGHTS FROM 200-PATIENT OBSERVATIONAL STUDY IN ACUTE MELIOIDOSIS, LAYING GROUNDWORK FOR PHASE 2 PROOF-OF-CONCEPT TRIAL OF EPETRABOROLE AN2 THERAPEUTICS INC - TO INITIATE PHASE 2 TRIAL LATER THIS YEAR Source text: ID:nBw6QVtwpa Further company coverage: ANTX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview